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Let’s make liver
 
etoxification is what livers do best, and regenerating 
after toxic insults is what livers do second best. All that 
proliferative capacity suggests that liver stem cells might be 
a very different and more prevalent beast than stem cells 
from other organs. But, on page 173, Suzuki et al. report 
that the fetal mouse liver, just like the adult bone marrow, has 
as its founder a relatively rare and undifferentiated cell type.
Suzuki et al. have attempted to isolate liver stem cells 
before, but their isolation strategy fell short of allowing 
clonal analysis. Now they add one additional selection 
marker (cMet, the receptor for hepatocyte growth factor) and 
use cell sorting to achieve a 560-fold enrichment for hepatic 
colony-forming units in culture (H-CFU-Cs). These single cells 
do not express markers for either hepatocytes or cholangiocytes 
(the cells that form bile ducts), and are capable of self-renewal 
both in vitro (single cells can be replated to yield more 
undifferentiated cells) and in vivo (recently divided cells 
have the undifferentiated phenotype). Signs of differentiation 
arise, however, with longer times in culture.
Even more extensive differentiation can be seen in vivo, 
with transplanted H-CFU-Cs growing to form functional parts 
of liver, bile duct, pancreas and intestine. Thus, Suzuki et al. 
may have discovered an endodermal stem cell, or at least a 
liver stem cell with impressive abilities to transdifferentiate if 
placed in the right environment. This flexibility may be paired 
with the superior proliferative capabilities of differentiated 
hepatocytes during the process of liver regeneration. 
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Progenitor cells express either liver (green) or bile duct (red) 
markers.
 
finally, to catenin tyrosine phosphory-
lation and establishment of cell–cell 
adhesion.
The same research group has previously 
shown that a PRK2 relative called PKC-
 
 
 
 
is activated during keratinocyte differ-
entiation and can phosphorylate Fyn. 
But this does not appear to result in 
catenin phosphorylation. Calautti et al. 
suggest that PRK2–Fyn may take care of 
catenins, while in another part of the cell 
PKC-
 
 
 
–Fyn may induce other aspects of 
terminal differentiation, such as a halt in 
cell division. In fact, two pools of Fyn 
exist in the keratinocytes, one of which is 
found in association with E-cadherin at 
cell–cell borders, and the other in the 
cytoplasm. Additional complications 
may arise in the PRK2–Fyn pathway, 
where other Rho-effector proteins may 
be needed to reinforce and sustain the 
signal responsible for Fyn activation. 
 
 
Activated Rho recruits p120
ctn to cell–cell 
adhesions.
 
Sticking together a signal
 
alautti et al. have taken a collection 
of proteins that affect cell adhesion 
in keratinocytes and linked them into a 
pathway (page 137). The result is a
simple sequence from Rho through to 
the phosphorylation of catenins associated 
with adherens junctions. But there 
are hints that reality may be more 
complex, with more side-branches 
and collaborations.
During differentiation of keratinocytes 
these skin cells strengthen their attachment 
to one another, and both Fyn kinase and 
Rho are activated. The ultimate effect of 
activating Rho—phosphorylation of 
catenins—requires Fyn. Calautti et al. 
link Rho and Fyn into the same pathway 
by showing that both activation of Rho 
and the interaction of Rho with the 
PRK2 kinase are sufficient and, in the 
case of Rho, required to turn on Fyn. 
PRK2, a Rho effector, increases Fyn 
C
 
activity after being added to a Fyn 
immunoprecipitate, although this effect 
may be indirect. Thus the pathway leads 
through Rho, PRK2, and Fyn, leading, 
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